Player FM - Internet Radio Done Right
Checked 2d ago
Added five years ago
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Metastatic Breast Cancer | Oncology Today with Dr Neil Love: An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast Cancer
Manage episode 435841990 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring an interview with Prof Giuseppe Curigliano, including the following topics:
- Counseling patients with newly diagnosed metastatic breast cancer (mBC); role of patient-reported outcomes and advocacy (0:00)
- Individualized selection of up-front therapy for patients with HR-positive, HER2-negative mBC (6:02)
- Selection and sequencing of treatment for patients with HR-positive, HER2-negative disease who experience progression on CDK4/6 inhibition (9:40)
- Current and future role of HER2-targeted therapy for HER2-low and HER2-ultralow mBC (19:46)
- Selection and sequencing of therapy for patients with metastatic triple-negative breast cancer (29:53)
- Emerging innovative interventions for the treatment of mBC (37:17)
1414 episodes
Manage episode 435841990 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring an interview with Prof Giuseppe Curigliano, including the following topics:
- Counseling patients with newly diagnosed metastatic breast cancer (mBC); role of patient-reported outcomes and advocacy (0:00)
- Individualized selection of up-front therapy for patients with HR-positive, HER2-negative mBC (6:02)
- Selection and sequencing of treatment for patients with HR-positive, HER2-negative disease who experience progression on CDK4/6 inhibition (9:40)
- Current and future role of HER2-targeted therapy for HER2-low and HER2-ultralow mBC (19:46)
- Selection and sequencing of therapy for patients with metastatic triple-negative breast cancer (29:53)
- Emerging innovative interventions for the treatment of mBC (37:17)
1414 episodes
All episodes
×1 Metastatic Triple-Negative Breast Cancer | Oncology Q&A for Patients with Metastatic Triple-Negative Breast Cancer 1:00:59
1:00:59
Play Later
Play Later
Lists
Like
Liked
1:00:59Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics: Introduction (0:00) Stages of Triple-Negative Breast Cancer (TNBC); Recurrence After Adjuvant Treatment (5:28) Long-Term Outcomes with Metastatic TNBC (11:55) Side Effects and Complications of Treatment (24:42) Dose Reduction (30:27) Working While Receiving Treatment (32:24) Support for Minor Children and Grandchildren (37:12) Second Opinions and Self Advocacy (42:53) Recording Clinic Visits; Complementary Therapies; Nutrition (48:38) Living Wills and Advanced Directives (55:41) Please take our survey…
1 Lymphoma | What Clinicians Want to Know: Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma 2:00:29
2:00:29
Play Later
Play Later
Lists
Like
Liked
2:00:29Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17) Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46) Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44) CME information and select publications…
1 Myelofibrosis | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Myelofibrosis 1:59:15
1:59:15
Play Later
Play Later
Lists
Like
Liked
1:59:15Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics: Introduction (0:00) Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Kuykendall (2:53) Managing MF for Patients with Thrombocytopenia — Dr Bose (32:45) Managing MF for Patients with Anemia — Dr Yacoub (59:47) Future Directions in the Management of MF — Dr Fleischman (1:27:53) CME information and select publications…
1 Metastatic Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of Metastatic Breast Cancer 2:01:00
2:01:00
Play Later
Play Later
Lists
Like
Liked
2:01:00Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy and Dr Sara M Tolaney, including the following topics: Introduction (0:00) Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop (10:17) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr Tolaney (37:54) Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Kalinsky (53:59) Tolerability Considerations with Approved and Investigational Antibody-Drug Conjugates — Dr O’Shaughnessy (1:14:16) Other Important Care Considerations for Patients with mBC — Dr Hamilton (1:41:30) CME information and select publications…
1 Chronic Myeloid Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia 1:27:00
1:27:00
Play Later
Play Later
Lists
Like
Liked
1:27:00Featuring perspectives from Prof Andreas Hochhaus, Dr Michael J Mauro and Dr B Douglas Smith, moderated by Dr Mauro, including the following topics: Introduction (0:00) Up-Front Therapy for Chronic Myeloid Leukemia (CML) — Prof Hochhaus (2:45) Management of Relapsed CML, Including in Patients with a T315I Mutation — Dr Mauro (29:23) Tolerability and Other Practical Issues with Commonly Employed CML Therapies — Dr Smith (1:00:15) CME information and select publications…
1 Acute Myeloid Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia 1:58:51
1:58:51
Play Later
Play Later
Lists
Like
Liked
1:58:51Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics: Introduction (0:00) Treatment for Older Patients with Acute Myeloid Leukemia (AML) — Prof Wei (2:48) Selection of Initial Therapy for Younger Patients with AML without a Targetable Mutation, Including Those with Secondary AML — Dr Stone (26:52) Role of FLT3 Inhibitors in AML Management — Dr Perl (49:41) Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Stein (1:13:57) Potential Role of Menin Inhibitors and Other Novel Agents in the Treatment of AML — Dr Wang (1:35:50) CME information and select publications…
1 Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Role of Endocrine-Based Therapy in the Management of Breast Cancer 2:00:37
2:00:37
Play Later
Play Later
Lists
Like
Liked
2:00:37Featuring perspectives from Dr Matthew P Goetz, Dr Sara A Hurvitz, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Hormone Receptor (HR)-Positive Localized Breast Cancer — Dr Hurvitz (12:21) Incorporation of CDK4/6 Inhibitors into the Management of HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Wander (34:36) Evolving Role of PI3K Inhibitors for HR-Positive mBC Harboring PIK3CA Mutations — Dr Goetz (57:58) Clinical Utility of AKT Inhibitors for Patients with Progressive HR-Positive mBC — Dr Jhaveri (1:15:52) Oral SERDs (Selective Estrogen Receptor Degraders) for HR-Positive mBC — Dr Kaklamani (1:37:24) CME information and select publications…
1 HER2-Low and HER2-Ultralow Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of HER2-Low and HER2-Ultralow Breast Cancer 1:31:29
1:31:29
Play Later
Play Later
Lists
Like
Liked
1:31:29Featuring perspectives from Dr Aditya Bardia, Prof Giuseppe Curigliano, Dr Hope S Rugo and Dr Antonio C Wolff, including the following topics: Introduction (0:00) Optimizing the Identification of HER2-Low and HER2-Ultralow Breast Cancer — Dr Wolff (2:28) Available Data with HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr Bardia (23:16) Practical Applications of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Metastatic Breast Cancer — Prof Curigliano (51:31) Future Directions for HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Breast Cancer — Dr Rugo (1:11:57) CME information and select publications…
1 Multiple Myeloma | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple Myeloma 1:57:11
1:57:11
Play Later
Play Later
Lists
Like
Liked
1:57:11Featuring perspectives from Dr Sagar Lonial, Prof Philippe Moreau, Dr Robert Z Orlowski, Dr Noopur Raje and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics: Introduction (0:00) Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Orlowski (1:26) Integration of Novel Therapies into the Management of Relapsed/Refractory MM — Dr Richardson (26:53) Chimeric Antigen Receptor T-Cell Therapy for MM — Dr Raje (48:48) Bispecific Antibodies for the Treatment of MM — Prof Moreau (1:12:52) Other Novel Agents and Strategies Under Investigation for MM — Dr Lonial (1:36:32) CME information and select publications…
1 Chronic Lymphocytic Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia 1:57:07
1:57:07
Play Later
Play Later
Lists
Like
Liked
1:57:07Featuring perspectives from Dr Farrukh T Awan, Dr Bita Fakhri, Dr Kerry A Rogers and Dr William G Wierda, moderated by Dr Jeff Sharman, including the following topics: Introduction (0:00) Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD (1:44) Emerging Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Combination with Bcl-2 Inhibitors — Kerry A Rogers, MD (25:43) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Farrukh T Awan, MD (49:20) Integration of Noncovalent BTK Inhibitors into the Management of Relapsed/Refractory CLL — Bita Fakhri, MD, MPH (1:11:52) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — William G Wierda, MD, PhD (1:35:06) CME information and select publications…
1 Colorectal and Gastroesophageal Cancers | Cases from the Community: Integrating New Research Findings into Practice 49:11
49:11
Play Later
Play Later
Lists
Like
Liked
49:11Featuring perspectives from Dr Christopher Lieu, moderated by Dr Stephen “Fred” Divers CME information and select publications
1 Hepatobiliary Cancers | Cases from the Community: Integrating New Research Findings into Practice 55:50
55:50
Play Later
Play Later
Lists
Like
Liked
55:50Featuring perspectives from Dr Daneng Li, moderated by Dr Stephen “Fred” Divers CME information and select publications
1 Gynecologic Cancers | Cases from the Community: Integrating New Research Findings into Practice 46:42
46:42
Play Later
Play Later
Lists
Like
Liked
46:42Featuring perspectives from Dr Kathleen N Moore, moderated by Dr Stephen “Fred” Divers CME information and select publications
1 Myelofibrosis | Cases from the Community: Integrating New Research Findings into Practice 51:44
51:44
Play Later
Play Later
Lists
Like
Liked
51:44Featuring perspectives from Dr Stephen T Oh, moderated by Dr Stephen “Fred” Divers CME information and select publications
1 ER-Positive Metastatic Breast Cancer | 5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer — Issue 2 11:59
11:59
Play Later
Play Later
Lists
Like
Liked
11:59Featuring an interview with Dr Seth Wander, including the following topics: Design of SERENA-6, a Phase III switching trial of camizestrant for ESR1-mutant breast cancer during first-line treatment Turner N et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol 2023;19(8):559-73. Abstract (0:00) EMERALD trial analysis of patient-reported outcomes with oral elacestrant compared to standard of care endocrine therapy for ER-positive, HER2-negative advanced or metastatic breast cancer Cortes J et al. EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy. ESMO Breast 2023; Abstract 188O . (5:50) Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2-directed therapy, with or without abemaciclib, for ER-positive, HER2-positive advanced breast cancer Bhave MA et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. ASCO 2024; Abstract 1027 . (9:43) CME information and select publications…
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.